TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03376984

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ND and AMOX modified Gutta Percha
Description: Gutta percha reinforced and modified with 5 nm diameter nanodiamonds and amoxicillin
Study: NCT05740462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recipes consumption
Description: Participants will eat two recipes a day for 17 weeks
Study: NCT03376984

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gutta Percha
Description: Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gutta Percha
Description: Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
Study: NCT05740462

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Recipes consumption
Description: Participants will eat two recipes a day for 17 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recipes consumption
Description: Participants will eat two recipes a day for 17 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hydroponic unit
Description: Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Hydroponic unit
Description: Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hydroponic unit
Description: Participants will grow vitamin B12 biofortified plants for 17 weeks and consume (10 grams) of plant material for 11 weeks.
Study: NCT06434701

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab sampling for COVID-19
Description: The healthcare provider will gently insert the swab a short distance (1-1.5 cm for young children) into one nostril, reaching the back of the nasal cavity. The swab will then be gently rotated and rubbed for a few seconds to collect a sample of mucus. The same process may be repeated in the other nostril.
Study: NCT06065072

Intervention type: DEVICE
Intervention: Optical measurement
Description: Optical measurements by optical biometers and an OCT

Intervention type: DEVICE
Intervention: Optical measurement
Description: Optical measurements by optical biometers and an OCT

Intervention type: DEVICE
Intervention: Optical measurement
Description: Optical measurements by optical biometers and an OCT
Study: NCT04691869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Achilles EXPII
Description: Portable ultrasound machine that measures a patient's bone density at the calcaneus.
Study: NCT05659290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib alternating with Bevacizumab plus Capecitabine
Description: Maintenance therapy with Fruquintinib 5mg, orally, once daily, d1-14, 2 weeks on/ 1 week off, q3w, followed by Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 6 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab plus Capecitabine
Description: Maintenance therapy with Bevacizumab 7.5 mg/kg, iv.gtt,d1,q3w + Capecitabine 850 mg/m2, orally, twice daily, d1-14, q3w; every 3 weeks as a treatment cycle; until unacceptable toxicity, withdrawal of informed consent, death, or other criteria for ending the study (whichever occurs earlier).
Study: NCT04931511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound betamethasone Injection(Gluteal muscle injection)
Description: Gluteal muscle injection(Compound betamethasone 1ml + Sodium Chloride Injection 4ml) + Subacromial Ultrasound Guided injection(Sodium Chloride Injection 5ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound betamethasone Injection(Subacromial Ultrasound Guided injection)
Description: Gluteal muscle injection (Sodium Chloride Injection 5ml)+ Subacromial Ultrasound Guided injection (corticosteroid 1ml+Sodium Chloride Injection 4ml)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: paticipant will be teached by the Physicaltherapist to reduce the shoulder pain at home

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: paticipant will be teached by the Physicaltherapist to reduce the shoulder pain at home
Study: NCT06584721

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-pronation taping (Low dye taping) + Conventional therapy
Description: They would be receiving treatment as follow:~Anti-pronation taping (Low dye taping) Applied on alternate days. 3 days / week for 4 weeks.~Conventional Therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 20 mins 2. William flexion exercises (5repsx1set). 3. Lower limb stretching exercises (3repsxset1, 10sec hold) 3sessions/ week.

Intervention type: OTHER
Group type: OTHER
Intervention: Short Foot Exercises + Conventional PT
Description: They would be receiving treatment as follow:~Short foot exercises are used to reduce the foot pronation: Frequency: 30 reps x 1 set, 30 sec hold and 10 sec relaxation for 4 weeks. 3 session/ week).~Short foot Exercises includes a four-week plan, 1- Shortening of foot in Anterior-posterior direction, 2- Increase medial longitudinal arch, 3- Balanced loading in standing, 4- Approximating Head of first, second meta-tarsal and calcaneus with patient in standing (single leg).~Conventional therapy includes 1. Tens biphasic mode, 90Hz, 100ms pulse width for 20 mins 2. William flexion exercises (5repsx1set). 3. Lower limb stretching exercises (3repsx1set, 10sec hold) 3sessions/ week.
Study: NCT05623761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BUCCOTHERM® Sensitive Gums with Fluoride
Description: Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums with Fluoride twice daily for 1 month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BUCCOTHERM® Sensitive Gums Fluoride-Free
Description: Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums Fluoride-Free twice daily for 1 month.
Study: NCT05169658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography
Description: Undergo FDG-PET and FDG-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and FDG-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT and FDG-PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study: NCT04655222

Intervention type: DRUG
Intervention: Interferon Beta Therapy
Description: Administered as specified in the treatment arm.
Study: NCT06577493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenazopyridine Hydrochloride 99.5 MG
Description: Experimental arm to take two 99.5 mg phenazopyridine hydrochloride by mouth for a total of 199mg immediately prior to start of urodynamic testing
Study: NCT05169658

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05168774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elamipretide
Description: Elamipretide is a tetra peptide with limited blood brain barrier penetration being developed for use in a variety of mitochondrial disorders, including FRDA, mitochondrial myopathy and Barth Syndrome.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elamipretide
Description: Elamipretide is a tetra peptide with limited blood brain barrier penetration being developed for use in a variety of mitochondrial disorders, including FRDA, mitochondrial myopathy and Barth Syndrome.
Study: NCT04127968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Children in intervention group will receive 50,000 IU vitamin A after being randomized.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oil
Description: Children in control group will receive equal volume of oil.
Study: NCT06219811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two implant -retained overdenture reinforced with Co-Cr framework
Description: The intervention is made from polymethylmethacrylate reinforced with cobalt chromium ( Co-Cr) framework.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Two implant -retained overdenture reinforced with PEEK framework
Description: The intervention is made from polymethylmethacrylate reinforced with Polyetherketoneketone ( PEEK) framework.
Study: NCT05315037

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance Training
Description: Bench press: Exercise performed with participant lying supine with hands in prone position. Barbell is lowered vertically from fully extended elbow position to sternum, then returned to starting position. Barbell will be weighted with plates dependent on their strength and workout demands.~Deadlift: Consists of gripping bar while in a squat position. Extension of ankles, knees, and hips while gripping the bar brings the weight up until joints are locked completing the exercise concentric portion. The eccentric lowering of the weight follows and consists of flexion of joints.~Seated overhead press machine: This multi-joint exercise, deltoid and trapezius are the prime movers and triceps are secondary movers, with hands on the grips and a position allowing back and buttocks to be completely supported. They push against a load vertically until glenohumeral joint fully extends, then load is returned to starting position and process continues until all repetitions desired are achieved
Study: NCT05338840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MULLIGAN ROTATIONAL MOVEMENT
Description: 12 sessions over 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medial gapping technique
Description: 12 sessions over 6 weeks
Study: NCT05897281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SHOOT exercise group
Description: In addition to routine training, the experimental group will be done a progressive resistance band exercise program (SHOOT) created for shooters, 3 days a week for 8 weeks, accompanied by a physiotherapist.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: routine training group
Description: The control group will continue their routine training
Study: NCT06149975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor-cognitive training
Description: The motor-cognitive training in this study will be conducted in form of a step-based dual-task training. A mat (approximately 90 x 90 cm) made from extra non-slip yoga mats is required. The mat is divided into 9 equal squares with a 3 x 3 pattern. Participants will be presented with stepping patterns which they must memorize and then execute on the mat in the pace given by a metronome. All participants will start at the same level. The progression will be adjusted individually according to the fixed criteria of the StepIt concept within the sessions. All sessions will be supervised by at least one physical therapist.
Study: NCT04280692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge
Description: Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-Pyrimethamine
Description: Sub-curative 500mg/25mg single dose regimen
Study: NCT05803538

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMS, telephone interview or diary card
Description: SMS, telephone interview or diary card

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMS, telephone interview or diary card
Description: SMS, telephone interview or diary card

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMS, telephone interview or diary card
Description: SMS, telephone interview or diary card

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SMS, telephone interview or diary card
Description: SMS, telephone interview or diary card
Study: NCT04280692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-Pyrimethamine
Description: Sub-curative 500mg/25mg single dose regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-Pyrimethamine
Description: Sub-curative 500mg/25mg single dose regimen
Study: NCT06128616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT
Description: Extracorporeal Shock Wave Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: Botulinum Toxin Type A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Botulinum Toxin Type A

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serial Casting
Description: Serial Casting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serial Casting
Description: Serial Casting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical Therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: Occupational Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Occupational Therapy
Study: NCT05625906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-media experiential training programme
Description: 1. Webpage and mobile applications of training material on ACP, to be offered four weeks before the workshop~2. A three-hour multimedia workshop (8-10 nurses per group) including enhanced lectures and a role play encounter with standardised patients. Immediate feedback on their quality of decision support skills will be given. The workshops will be delivered by an experienced advance practice nurse with a palliative care specialty.~3. Writing a reflective journal after the role play with standardised patients
Study: NCT06039748

Intervention type: OTHER
Intervention: AngioQFA
Description: FFR measured by pressure wire, AngioQFA computed by coronary angiographic images
Study: NCT06175819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuka honey( MgO 850, UMF+20) loaded nano-formulation
Description: Assessment of the efficacy of manuka-loaded nano-formulation and manuka honey-loaded gel on the improvement of acne vulgaris

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuka honey( MgO 850, UMF+20) loaded nano-formulation
Description: Assessment of the efficacy of manuka-loaded nano-formulation and manuka honey-loaded gel on the improvement of acne vulgaris

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manuka honey( MgO 850, UMF+20) loaded nano-formulation
Description: Assessment of the efficacy of manuka-loaded nano-formulation and manuka honey-loaded gel on the improvement of acne vulgaris
Study: NCT06539455

Intervention type: DRUG
Intervention: standard anti-TB treatment
Description: standard anti-TB treatment in line with international guidelines (isoniazid , rifampin, ethambutol, and pyrazinamide)

Intervention type: DRUG
Intervention: standard anti-TB treatment
Description: standard anti-TB treatment in line with international guidelines (isoniazid , rifampin, ethambutol, and pyrazinamide)
Study: NCT04495673

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Participants receive 10 sessions (2 5-visit blocks of 46 minutes) of active tDCS to DLPFC (dorsolateral prefrontal cortex)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Participants receive 10 sessions (1 5-visit block of 46 minutes of active tDCS and 1 5-visit block of sham tDCS)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Executive functioning tasks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Executive functioning tasks
Study: NCT05807347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: VA regimen Drug: Venetoclax orally once daily (100 mg d1, 200 mg d2, 400 mg d3-21); Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7. CAG regimen Drug: Cytarabine 10mg/m2 subcutaneously q12h on days 1-7 Drug: Aclacinomycin 12-14mg/m2 on days 1,3,5,7 Drug: Granulocyte colony-stimulating factor 5ug/kg on days 0-8, discontinue if WBC \>20×109/L
Study: NCT05951556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of BCI
Description: Clients will utilize BCI with training to communicate wants and needs
Study: NCT05006625

Intervention type: OTHER
Intervention: Collaborative Care Model
Description: Use of the collaborative care model to screen and deliver care for depression in adolescents and young adults aged 15-24 years seeking HIV prevention and treatment services

Intervention type: OTHER
Intervention: Collaborative Care Model
Description: Use of the collaborative care model to screen and deliver care for depression in adolescents and young adults aged 15-24 years seeking HIV prevention and treatment services
Study: NCT05978323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention
Description: Short face-to-face intervention interviews will be conducted with individuals in the intervention group. Interviews will be held in primary healthcare organizations' meeting rooms. Brief intervention interviews will be conducted with the intervention group. It was determined as the first evaluation and the follow-ups on the 1st day, 15th day, 1st month, 3rd month, and the last evaluation (6th month). Brief interventions, 5A for those who are ready to change their behavior (Ask, Advise, Assess, Assist, Arrange); Those who are not ready to change their behavior 5R (Relevance, Risks, Rewards, Roadblocks, Repetition) model will be used. Brief intervention interviews will take an average of 20-30 minutes. The talks will include awareness of overweight and obesity, a healthy diet, and exercise. By the researcher's prepared will be used for individuals with low health literacy educational materials.
Study: NCT04743908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Network Strategy + COVID-19 messaging
Description: Contextually adapted and theory-driven messages - misinformation correction and self-affirmation - to increase awareness, self-efficacy and community engagement in our adapted Social Network testing Strategy (SNS). SNS is an evidence-based testing intervention that has been widely used in multiple settings with marginalized individuals (ie substance-users) who facilitate the recruitment of their social contacts into testing services.
Study: NCT04896827

Intervention type: OTHER
Intervention: Conditioned pain modulation test
Description: Conditioned pain modulation (CPM) protocol consist of evaluating pain during a heat test, before and after one conditioning stimulus (cold water bath); 3 cameras will be capturing participants' facial expressions during the tests.

Intervention type: OTHER
Intervention: Conditioned pain modulation test
Description: Conditioned pain modulation (CPM) protocol consist of evaluating pain during a heat test, before and after one conditioning stimulus (cold water bath); 3 cameras will be capturing participants' facial expressions during the tests.
Study: NCT04830163

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Brain state-dependent paired corticomotoneuronal stimulation (PCMS)
Description: Paired corticomotoneuronal stimulation (PCMS) involves delivering precisely timed pairs of transcranial magnetic stimulation (TMS) and peripheral nerve stimulation (PNS) so that the neuronal activity evoked by such stimulation arrives synchronously at corticospinal-motoneuronal synapses. This synchronous arrival is postulated to cause long-term potentiation via spike timing-dependent plasticity, which then improves corticospinal transmission and hand function. In this study, paired corticomotoneuronal stimulation (PCMS) will be applied during specific brain states that reflect increased recruitment of motoneurons via the corticospinal tract. This increased recruitment is expected to enhance the beneficial effects of PCMS on human hand function after stroke.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Brain state-dependent paired corticomotoneuronal stimulation (PCMS)
Description: Paired corticomotoneuronal stimulation (PCMS) involves delivering precisely timed pairs of transcranial magnetic stimulation (TMS) and peripheral nerve stimulation (PNS) so that the neuronal activity evoked by such stimulation arrives synchronously at corticospinal-motoneuronal synapses. This synchronous arrival is postulated to cause long-term potentiation via spike timing-dependent plasticity, which then improves corticospinal transmission and hand function. In this study, paired corticomotoneuronal stimulation (PCMS) will be applied during specific brain states that reflect increased recruitment of motoneurons via the corticospinal tract. This increased recruitment is expected to enhance the beneficial effects of PCMS on human hand function after stroke.
Study: NCT05542836

Intervention type: BEHAVIORAL
Intervention: Expedited postoperative activity instructions
Description: Ad lib postoperative activity and return to work recommendations

Intervention type: BEHAVIORAL
Intervention: Standard postoperative activity restructions
Description: Standard conservative postoperative activity and return to work recommendations
Study: NCT06499870

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples